Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23860940 | 1.00 | CRBN (0.57) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL23860903 | 0.88 | IKZF2 (0.50) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30133350 | 0.88 | IKZF2 (0.50) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30133331 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL23861010 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL30133260 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL23860875 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL23860973 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL30133258 | 0.87 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL23860862 | 0.85 | CRBN (0.55) | CRBNIKZF2IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | claimed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | claimed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |